EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 360 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Foodie Fridays: Farmer’s Market Finds July 16, 2021 GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... February 2, 2021 Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours March 1, 2021 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 Load more HOT NEWS Searching for novel connections in cancer metabolism An Important Part of Cancer Caregiving That’s Often Overlooked and How... 20 years of Cancer Research UK: Celebrating our research nurses A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with...
